Bacterial coinfections with coronavirus disease 2019 (COVID-19)

Glen Huang DO1, Daisuke Furukawa MD2, Bryant D. Yang MD1, Brian J. Kim PharmD2 and Arthur C. Jeng MD1,3

1Division of Infectious Diseases, Department of Medicine, University of California – Los Angeles, Los Angeles, California, 2Department of Pharmacy, Olive View - University of California Los Angeles Medical Center, Sylmar, California and 3Division of Infectious Diseases, Department of Medicine, Olive View - University of California Los Angeles Medical Center, Sylmar, California

Abstract

Background: The pandemic caused by severe acute respiratory coronavirus virus 2 (SARS-CoV-2) has dramatically increased cheshospitalizations, and it is often difficult to determine whether there is a bacterial or fungal coinfection at time of presentation. In this study, we sought to determine the rates of coinfection and utilization of antibiotics in SARS-CoV-2 disease.

Methods: Retrospective chart review of patients hospitalized with COVID-19 pneumonia from April 13, 2020, to July 14, 2020.

Results: In total, 277 patients were hospitalized for COVID-19 pneumonia during this period. Patients that received antibiotics within 48 hours of presentation were more likely to be febrile (59.3% vs 41.2%; \( P = .01 \)) and to have leukocytosis (23.9% vs 5.9%; \( P < .01 \)) and were less likely to have a procalcitonin level <0.25 ng/mL (58.8% vs 74.5%; \( P = .04 \)). In total, 45 patients had positive blood cultures collected during hospitalization, 16 of which were clinically significant. Of the clinically significant blood cultures, 5 were collected <48 hours of admission. Moreover, 18 sputum cultures were clinically significant, 2 of which were collected within 48 hours of admission.

Conclusion: Bacterial and fungal coinfections in COVID-19 appear to be rare on presentation; thus, this factor may be a good target for enhanced antibiotic stewardship.

(Received 14 April 2021; accepted 23 July 2021)
(within 48 hours of admission) or late (after 48 hours). The class, specific antibiotics, and days of therapy were abstracted by manual chart review.

**Statistical analysis**

Categorical variables were analyzed using the $\chi^2$ or Fisher exact test. Continuous variables were evaluated using the Student $t$ test or the Mann-Whitney $U$ test where appropriate.

**Results**

Overall, 684 patients with a positive SARS-CoV-2 nasopharyngeal PCR between April 13, 2020, to July 14, 2020, were included. Of these, 277 had been admitted for COVID-19 pneumonia and either died during their hospitalization or were discharged. Also, 51 patients did not receive antibiotics within 48 hours of hospitalization and 226 patients did (Table 1). The overall mean length of stay was 8.5 days (range, 0–75). Individuals who did not receive antibiotics within 48 hours were less likely to be febrile (41.2% vs 59.3%; $P = .01$) and were less likely to have leukocytosis (5.9% vs 23.9%; $P < .01$), neutrophilia (9.8% vs 31.4%; $P < .01$), or lymphopenia (56.9% vs 71.2%; $P < .01$). They were more likely to have chest radiograph findings that were negative for any acute processes (23.5% vs 8.8%; $P < .01$). In terms of inflammatory markers, individuals who were not administered antibiotics within 48 hours of hospitalization had lower mean levels of D-dimer (0.73 vs 0.97; $P = .04$) and higher levels of lactate dehydrogenase (277.5 vs 329; $P = .09$) and ferritin (369 vs 801; $P < .01$). Individuals who did not receive antibiotics within 48 hours were also less likely to have procalcitonin levels above 0.5 ng/mL (2 vs 47; $P < .01$).

**Table 1. Characteristics of Patients With COVID-19**

| Characteristic | Did Not Receive Antibiotics Within 48 Hours of Hospitalization | Received Antibiotics Within 48 Hours of Hospitalization | $P$ Value |
|---------------|---------------------------------------------------------------|--------------------------------------------------------|-----------|
| Demographics  |                                                               |                                                        |           |
| Age, y        | 54.5 (46–63.25)                                               | 56 (46–69)                                             | .21       |
| No comorbidities | 10 (19.6)                                                    | 51 (22.6)                                              | .65       |
| Hypertension  | 23 (45.1)                                                    | 94 (41.6)                                              | .65       |
| Diabetes mellitus | 22 (43.1)                                                   | 78 (34.5)                                              | .25       |
| Coronary artery disease | 3 (5.9)                                                       | 11 (4.9)                                               | .73       |
| Congestive heart failure | 6 (11.8)                                                     | 6 (2.7)                                                | .01       |
| Chronic kidney disease | 6 (11.8)                                                      | 29 (12.8)                                              | .84       |
| End-stage kidney disease | 2 (3.9)                                                      | 10 (4.4)                                               | .87       |
| Lung disease  | 4 (7.8)                                                      | 16 (7.1)                                               | .77       |
| Cirrhosis     | 2 (3.9)                                                      | 5 (2.2)                                                | .62       |
| From skilled nursing facility or long-term acute-care facility | 6 (11.8)                                          | 42 (18.6)                                              | .25       |
| Clinical presentation |                                                        |                                                        |           |
| Patient febrile within first 24 h | 21 (41.2)                                                   | 134 (59.3)                                             | .01       |
| White blood cells ×10⁹ cells/L | 6.4 (5.3–7.6)                                            | 10.2 (6.2–10.7)                                         | <.01      |
| Presence of leukocytosis (white blood cells >10.5 × 10⁹ cells/L) | 3 (5.9)                                                   | 54 (23.9)                                              | <.01      |
| Presence of neutrophilia (neutrophils >8 × 10⁹ cells/L) | 5 (9.8)                                                   | 71 (31.4)                                              | <.01      |
| Presence of lymphopenia (lymphocytes <0.8 × 10⁹ cells/L) | 29 (56.9)                                                | 161 (71.2)                                             | .04       |
| D-Dimer (mcg/mL)$^b$ | 0.73 (0.48–1.41)                                              | 0.97 (0.58–1.85)                                       | .04       |
| Lactate dehydrogenase (U/L) $^{a,b}$ | 277.5 (193–361)                                            | 329 (243.3–329)                                        | .09       |
| Ferritin (mcg/L)$^b$ | 369 (209.5–607.3)                                        | 801 (415.5–1499.3)                                    | <.01      |
| C-reactive protein (mg/L)$^b$ | 73.3 (30.3–163.7)                                          | 137.7 (69.2–200.8)                                     | <.01      |
| Procalcitonin (ng/mL)$^b$ | 0.09 (0.05–0.11)                                           | 0.15 (0.08–0.41)                                       | <.01      |
| Procalcitonin <0.25 ng/mL$^b$ | 38 (74.5)                                                 | 133 (58.8)                                             | .04       |
| Procalcitonin 0.26–0.5 ng/mL$^b$ | 1 (2)                                                      | 33 (14.6)                                              | <.01      |
| Procalcitonin > 0.5 ng/mL$^b$ | 2 (3.9)                                                   | 47 (20.8)                                              | <.01      |
| Lobar findings on chest radiograph | 5 (9.8)                                                   | 30 (13.3)                                              | .64       |
| Chest radiograph negative for acute process | 12 (23.5)                   | 20 (8.8)                                               | <.01      |
| Outcomes      |                                                               |                                                        |           |
| Supplemental oxygen required during hospitalization | 29 (56.9)                                          | 201 (88.9)                                             | <.01      |
| Intubation required during hospitalization | 0                                                        | 45 (19.9)                                              | <.01      |
| Duration of hospitalization, d | 2 (1–4)                                                       | 6 (3–12.25)                                             | <.01      |
| In-hospital mortality | 3 (5.9)                                                   | 42 (18.6)                                              | .03       |

$^a$Continuous variables are expressed as median (interquartile range).

$^b$First value obtained on admission.

Glen Huang et al.
P = .04), ferritin (369 vs 801; P < .01), and C-reactive protein (73.3 vs 137.7; P < .01); they were also more likely to have a procalcitonin level <0.25 ng/mL (74.5% vs 58.8%; P = .04). We detected no statistically significant differences in symptoms between the 2 groups. Patients who were not administered antibiotics were less likely to have supplemental oxygen (56.9% vs 88.9%; P < .01) or intubation (0% vs 19.9%; P < .01) during the admission. They also had a lower in-hospital mortality rate (5.9% vs 18.6%; P = .03).

In total, 45 (16.2%) patients had positive blood cultures during their hospitalization (Fig. 1). Among these patients, 16 (36.6%) cultures were clinically significant, and 5 were collected <48 hours after admission. The median time to collection of blood culture for gram-negative bacteremia was 9.5 days (range, 0–55), and the median time to collection of blood culture for *Candida* spp fungemia was 6 days (range, 14–24). For patients with positive sputum cultures (Fig. 1), 18 (56.3%) cultures were clinically significant, of which 2 were collected <48 hours after admission. The median time to collection of positive gram-negative sputum culture was 17 days (range, 1–30).

Of the antibiotics initiated within 48 hours, azithromycin was the most used agent, followed by ceftriaxone. Azithromycin monotherapy was used in 43 patients (19%). Anti-pseudomonal and anti–methicillin-resistant *Staphylococcus aureus* (MRSA) antibiotics were prescribed in 13.8% and 11.6% of patients who had antibiotics initiated within 48 hours of admission, respectively, with median durations of 2 days and 1 day, respectively. When an antibiotic was initiated after 48 hours, the most commonly used was vancomycin, followed by cefepime, with median durations of 3 and 5.5 days, respectively (Table 2). In total, the median duration of all antibiotics was 5 days (interquartile range [IQR], 5–6).

### Discussion

The current pandemic is unprecedented, with high mortality. Although prescriber utilization of broad-spectrum antibiotics has been documented in the literature, the circumstances in which they are used have not been well studied. A published study in Michigan analyzed 1,705 patients with COVID-19 and aimed to describe the number of bacterial coinfections. In that study, 56.6% of patients were prescribed early antibiotic therapy, and only 3.5% of patients had confirmed community-onset bacterial infections. Our study showed similar rates of antibiotic use despite low rates of culture confirmed bacterial coinfections. It appears that patients with clinically significant cultures (either sputum or blood) tended to have cultures collected several days into their hospitalization in our study, suggesting nosocomial acquisition.

Previous studies have noted an increase in antibiotic utilization in both “narrow” and “broad-spectrum” categories; however, these studies do not have patient-level data on the duration and timing with which each antibiotic was prescribed. Not surprisingly,

### Table 2. Utilization of Antibiotics Within and After 48 Hours of Hospitalization

| Category of Antibiotic | Antibiotics Initiated Within 48 Hours of Hospitalization (n = 228), No. (%)<sup>a</sup> | Median Days on Antibiotics Initiated Within 48 Hours of Hospitalization (IQR) | Antibiotics Initiated After 48 Hours of Hospitalization (n = 55), No. (%)<sup>a</sup> | Median Days on Antibiotics Initiated After 48 Hours of Hospitalization (IQR) |
|------------------------|-------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Anti-pseudomonal agent | 31 (13.7)                                       | 2 (1–3)                             | 36 (65.5)                          | 6 (3–10)                            |
| Cefepime               | 14 (6.2)                                        | 3 (1.75–6.25)                      | 24 (43.6)                          | 5.5 (3–8.5)                         |
| Piperacillin–tazobactam| 13 (5.8)                                        | 1 (1–2.5)                          | 9 (16.4)                           | 5 (3–8)                             |
| Meropenem              | 5 (2.2)                                         | 1 (1–1.5)                          | 6 (10.9)                           | 3 (2.5–4.25)                        |
| Aminoglycoside         | 2 (0.9)                                         | 1.5                                | 2 (3.6)                            | 1                                   |
| Anti-MRSA agent        | 26 (11.5)                                       | 1 (1–2.25)                         | 32 (58.2)                          | 3 (2–6)                             |
| Vancomycin             | 26 (11.5)                                       | 1 (1–2.25)                         | 32 (58.2)                          | 3 (2–5)                             |
| Linezolid              | 0                                               | 1 (1.8)                            | 8                                  |                                     |
| Daptomycin             | 0                                               | 1 (1.8)                            | 2                                  |                                     |
| Ceftaroline            | 0                                               | 1 (1.8)                            | 1                                  |                                     |
| Narrow-spectrum β-lactam<sup>b</sup> | 155 (68.6) | 4 (1–5)                            | 17 (30.9)                          | 5 (2–9.25)                         |
| Ceftriaxone            | 151 (66.8)                                      | 4 (1–5)                            | 9 (16.4)                           | 4 (1.5–6)                           |
| Amoxicillin–clavulanic acid | 1 (0.4)                  | 4 (7.3)                            | 3                                  |                                     |
| Amoxicillin            | 1 (0.4)                                         | 5                                  | 2 (3.6)                            | 5                                  |
| Ampicillin             | 1 (0.4)                                         | 1                                  | 1 (1.8)                            | 2                                  |
| Ampicillin–sulbactam   | 1 (0.4)                                         | 2                                  | 1 (1.8)                            | 4                                  |
| Cefazolin              | 1 (0.4)                                         | 1                                  | 2 (3.6)                            | 8                                  |
| Cephalaxin             | 2 (0.9)                                         | 4                                  | 0                                  |                                     |
| Azithromycin<sup>c</sup> | 211 (93.4)                                | 5 (5–5)                            | 1 (1.8)                            | 5                                  |
| Levofoxacin<sup>c</sup> | 2 (0.9)                                  | 3                                  | 2 (3.6)                            | 2.5                                |
| Ciprofoxacin<sup>c</sup> | 0                                           | 4 (7.3)                            | 4.5 (4–5)                          |                                     |

<sup>a</sup>Continuous variables are expressed as median (interquartile range).

<sup>b</sup>Narrow-spectrum β-lactams defined as a noncarbapenem β-lactam agent that does not cover pseudomonas or MRSA.

<sup>c</sup>Fluoroquinolones not included in anti-pseudomonal category.
in our study therapeutics targeting community-acquired pathogens (eg, ceftriaxone and azithromycin) were the antibiotics most commonly prescribed within 48 hours of admission. Broad-spectrum agents were still used during this period; however, they were generally de-escalated quickly with a median duration of \(\approx 1\) day. At our institution, broad-spectrum agents have prespecified indications. All antibiotic use, however, is reviewed by our antibiotic stewardship team, who then help in the de-escalation of therapy. Our data also suggest that most broad-spectrum antibiotic use occurred later in the hospitalization rather than as empiric therapy on admission.

One explanation of the use of empiric antibiotics in patients is the difficulty in distinguishing between a bacterial process and COVID-19. Recent guidelines have suggested empiric antibiotics for patients with suspected but unconfirmed COVID-19, and the World Health Organization has recommended empiric antibiotic therapy for severe COVID-19. Our results indicate that patients were more likely to get antibiotics in the presence of certain clinical parameters such as fevers or leukocytosis; however, these signs are nonspecific and are not specifically characteristic of a bacterial infection.

Our study had several limitations. It was a single-center retrospective study, so our findings may not be generalizable to all hospitals. Not all patients had blood and/or sputum cultures drawn during the hospitalization, making it hard to distinguish the true secondary infection rate. Also, a pneumonia multiplex PCR film array panel was not routinely used for community-acquired pneumonia at our hospital, so we may have underestimated the true incidence of bacterial coinfection. This diagnostic test would have a higher sensitivity in identifying bacteria than routine cultures would. Lastly, rates of antibiotic use may have been overestimated because azithromycin, which was used as a COVID-19–specific therapy early in the pandemic, was included in our analysis as an antibiotic therapy.

Antimicrobial resistance continues to be a global crisis. COVID-19 presenting similarly to a bacterial process has certainly not helped in efforts to curb antibiotic use. In our study, the rate of concurrent bacterial processes in COVID-19, as defined by culture-positivity, was very low but antibiotic use was widespread. The pandemic therefore raises a unique stewardship opportunity, and future studies are needed to better characterize the utility of antibiotics in the management of patients with COVID-19, so that its unnecessary antibiotic use can be minimized.

**Acknowledgments.**

**Financial support.** No financial support was provided relevant to this article.

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

**References**

1. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Johns Hopkins University website. https://coronavirus.jhu.edu/map.html. Accessed January 24, 2021.
2. Clancy CT, Nguyen MH. COVID-19, superinfections and antimicrobial development: What can we expect? *Clin Infect Dis* 2020. doi: 10.1093/cid/ciaa524.
3. Nestler M, Godbout E, Lee K, *et al.* Impact of COVID-19 on pneumonia-focused antibiotic use at an academic medical center. *Infect Control Hosp Epidemiol* 2020. doi:10.1017/ice.2020.362.
4. Beović B, Doušak M, Ferreira-Coimbra J, *et al.* Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey. *J Antimicrob Chemother* 2020. doi: 10.1093/jac/dkaa326.
5. Metlay JP, Waterer GW. Treatment of community-acquired pneumonia during the coronavirus disease 2019 (COVID-19) pandemic. *Ann Intern Med* 2020;173:304–305.
6. Clinical management of COVID-19. World Health Organization website. https://www.who.int/publications/i/item/clinical-management-of-covid-19. Accessed September 6, 2020.
7. Abellan-Alonso G, Padullés A, Rombauts A, *et al.* Antibiotic prescription during the COVID-19 pandemic: a biphasic pattern. *Infect Control Hosp Epidemiol* 2020;41:1371–1372.
8. Vaughn VM, Gandhi TN, Petty LA, *et al.* Empiric antibiotic therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study. *Clin Infect Dis* 2021;72: e533–e541.
9. Aslam B, Wang W, Arshad MI, *et al.* Antibiotic resistance: a rundown of a global crisis. *Infect Drug Resist* 2018;11:1645–1658.